CALCA and migraine disorder: After pooling, the change in monthly migraine days from baseline to endpoint was significantly greater for CGRP mAbs compared to placebo [weighted mean difference (WMD) = − 1.44, 95% CI = (− 1.68, − 1.19), I2 = 6%, p < 0.00001].